Gold nanoparticles for combined cancer treatment and imaging

Gold nanoparticles as theranostic agents in cancer occupy a promising boundary between laboratory nanoscience and translational oncology. By combining diagnostic imaging with targeted treatment in a single carrier, these particles can help clinicians locate a tumour, assess its response and deliver therapy through fewer separate interventions. Their appeal comes from a tuneable gold core, adaptable surface chemistry and compatibility with imaging, heat generation, drug delivery and radiosensitisation.

The 16th International Symposium on Applied Bioinorganic Chemistry, held in Ioannina, Greece, in June 2023 and organised by the University of Ioannina, provided a forum for researchers working across chemistry, medicine and materials science. The gathering examined how molecular design and biological evaluation can move advanced diagnostic and therapeutic concepts toward credible clinical applications.

Why theranostic gold nanoparticles matter

Theranostics links a diagnostic function with a therapeutic response, allowing treatment to be guided by the location and characteristics of a tumour. In gold nanoparticle systems, this can involve a particle that becomes visible under an imaging method, carries a drug to a selected target, or changes its behaviour when exposed to light, heat or radiation. Surface ligands can provide active targeting, while the gold core supplies intrinsic optical and electronic properties.

Several treatment strategies can be built around these materials. Gold nanoparticles may act as contrast agents for computed tomography or photoacoustic imaging, generate heat for photothermal therapy, transport anticancer drugs, or increase the sensitivity of nearby tissue to radiotherapy. Combining these functions may improve dose control and permit treatment decisions to be reassessed as a tumour evolves.

Translation requires equally careful attention to biological limitations. Protein adsorption, rapid clearance by the liver and spleen, incomplete tumour penetration and variation between cancer types can alter performance. Particle size, shape, coating and charge must therefore be evaluated alongside toxicity, pharmacokinetics and the heterogeneity of the tumour microenvironment.

Designing nanoparticles for clinical relevance

A reproducible therapeutic platform begins with controlled synthesis and quantitative characterisation. Transmission electron microscopy can reveal core size and morphology, while dynamic light scattering, zeta-potential measurements and ligand analysis help describe the particles in solution and under biological conditions. These details affect cellular uptake, circulation time and manufacturing consistency, making standardised protocols essential across laboratories.

Preclinical studies should connect physical characterisation with meaningful biological endpoints. Biodistribution, clearance, immune response and toxicity require consistent dosing, while tumour models must represent the vascular barriers and treatment resistance found in patients. Researchers should also consider whether adding a targeting ligand improves performance enough to justify extra complexity, regulatory scrutiny and cost.

Conference networks help researchers refine these questions before committing to an experimental programme. Prospective collaborators can compare the symposium community with the 2015 conference site, keeping discussions connected to wider inorganic and coordination-chemistry research networks and creating pathways for shared methods or facilities.

Supporting participation and career development

The symposium programme explained routes for participation and recognition, including young scientist travel awards, poster prizes, scholarships and the associated application requirements. Such support is particularly valuable where early-career researchers need time, funding and an international network to develop their work. Presenting a poster also offers a direct way to test the clarity of a scientific argument with specialists outside the immediate research group.

Mentoring was an important part of that environment. The symposium’s women in bioinorganic chemistry panel discussion and mentoring programme highlighted the value of visible role models, constructive feedback and sustained professional networks. These conversations help address barriers that can otherwise restrict participation and progression in technical fields.

Poster competition and abstract sessions encouraged researchers to communicate not only results, but also the decisions behind experimental design. Questions about reproducibility, safety, scale-up and clinical translation received attention alongside conventional performance data. This wider view is essential for gold nanoparticles, whose laboratory promise depends on coordinated work across chemistry, biology, imaging and clinical practice.

Connecting the science with Australian research

Australian cancer research is distributed across distinct centres and collaborative networks. Melbourne’s Parkville biomedical precinct, Sydney’s Westmead health and research precinct, and university-hospital partnerships in Brisbane and Perth create strong environments for nanoscience and oncology. Each region offers different strengths in imaging, drug development, clinical trials and regulatory expertise, making national collaboration valuable rather than optional.

Funding structures also shape how a nanoparticle programme develops. Australian teams commonly combine National Health and Medical Research Council and Medical Research Future Fund support with state investment, philanthropic grants and partnerships with biotechnology companies. Hospital procurement can be demanding, so a commercial case must address manufacturing reliability, intellectual property, reimbursement and evidence alongside scientific performance.

Australia’s geography adds practical constraints. Multicentre studies require dependable sample shipping, cold-chain procedures, staff training and consistent data collection across sites. The same features of the health system that support a “centre of excellence” model can make broad recruitment slower, particularly when participants are spread across regional and remote areas.

Giving a platform a fair go is familiar Australian shorthand for providing a genuine opportunity to compete. Applied here, it means allowing a promising lead candidate to be tested under standardised conditions before teams commit substantial resources. For Greek-Australian researchers in Melbourne and Sydney, Ioannina also provides a direct bridge to an international scientific community and a setting in which new collaborations can form.

Engage with the symposium secretariat

Researchers planning future participation or seeking a follow-up collaboration should review the available guidance on symposium activities, travel awards, scholarships, poster prizes and application requirements. Zita Congress & Event Management serves as the official secretariat for registration, accommodation and abstract-related enquiries, providing a clear route for practical information.

A focused first message should identify the research question, the proposed scientific audience and the support required. That gives the secretariat the context needed to respond efficiently, while helping organisers connect prospective participants with the right programme, funding route or collaborative network. Contact the official team and turn the symposium’s interdisciplinary discussion into a concrete research pathway.